Skip to main content

TOBI Podhaler FDA Approval History

FDA Approved: Yes (First approved March 22, 2013)
Brand name: TOBI Podhaler
Generic name: tobramycin
Dosage form: Inhalation Powder
Company: Novartis Pharmaceuticals Corporation
Treatment for: Cystic Fibrosis

TOBI Podhaler (tobramycin inhalation powder) is an antibacterial aminoglycoside indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa.

Development timeline for TOBI Podhaler

Mar 24, 2013Approval FDA Approves TOBI Podhaler to Treat a Type of Bacterial Lung Infection in Cystic Fibrosis Patients

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.